Logo image of BBNX

BETA BIONICS INC (BBNX) Stock Price, Quote, News and Overview

NASDAQ:BBNX - Nasdaq - US08659B1026 - Common Stock - Currency: USD

16.42  +0.02 (+0.12%)

After market: 16.3 -0.12 (-0.73%)

BBNX Quote, Performance and Key Statistics

BETA BIONICS INC

NASDAQ:BBNX (8/4/2025, 8:00:01 PM)

After market: 16.3 -0.12 (-0.73%)

16.42

+0.02 (+0.12%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap713.78M
Shares43.47M
Float38.33M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO01-30 2025-01-30


BBNX short term performance overview.The bars show the price performance of BBNX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20 -30

BBNX long term performance overview.The bars show the price performance of BBNX in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of BBNX is 16.42 USD. In the past month the price increased by 22.54%.

BETA BIONICS INC / BBNX Daily stock chart

BBNX Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 26.52 226.06B
ISRG INTUITIVE SURGICAL INC 60.04 173.27B
BSX BOSTON SCIENTIFIC CORP 37.73 157.99B
SYK STRYKER CORP 29.69 145.79B
MDT MEDTRONIC PLC 16.3 114.85B
IDXX IDEXX LABORATORIES INC 56.85 54.91B
BDX BECTON DICKINSON AND CO 12.7 51.27B
EW EDWARDS LIFESCIENCES CORP 31.16 46.98B
RMD RESMED INC 30.52 42.73B
GEHC GE HEALTHCARE TECHNOLOGY 15.16 32.34B
DXCM DEXCOM INC 44.85 29.90B
PHG KONINKLIJKE PHILIPS NVR- NY 16 25.73B

About BBNX

Company Profile

BBNX logo image Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 291 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.

Company Info

BETA BIONICS INC

11 Hughes

Irvine CALIFORNIA US

Employees: 291

BBNX Company Website

BBNX Investor Relations

Phone: 19494277785

BETA BIONICS INC / BBNX FAQ

What is the stock price of BETA BIONICS INC today?

The current stock price of BBNX is 16.42 USD. The price increased by 0.12% in the last trading session.


What is the ticker symbol for BETA BIONICS INC stock?

The exchange symbol of BETA BIONICS INC is BBNX and it is listed on the Nasdaq exchange.


On which exchange is BBNX stock listed?

BBNX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BETA BIONICS INC stock?

15 analysts have analysed BBNX and the average price target is 24.03 USD. This implies a price increase of 46.33% is expected in the next year compared to the current price of 16.42. Check the BETA BIONICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BETA BIONICS INC worth?

BETA BIONICS INC (BBNX) has a market capitalization of 713.78M USD. This makes BBNX a Small Cap stock.


How many employees does BETA BIONICS INC have?

BETA BIONICS INC (BBNX) currently has 291 employees.


What are the support and resistance levels for BETA BIONICS INC (BBNX) stock?

BETA BIONICS INC (BBNX) has a support level at 15.02 and a resistance level at 16.43. Check the full technical report for a detailed analysis of BBNX support and resistance levels.


Is BETA BIONICS INC (BBNX) expected to grow?

The Revenue of BETA BIONICS INC (BBNX) is expected to grow by 30.6% in the next year. Check the estimates tab for more information on the BBNX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BETA BIONICS INC (BBNX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BETA BIONICS INC (BBNX) stock pay dividends?

BBNX does not pay a dividend.


What is the Price/Earnings (PE) ratio of BETA BIONICS INC (BBNX)?

BETA BIONICS INC (BBNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).


What is the Short Interest ratio of BETA BIONICS INC (BBNX) stock?

The outstanding short interest for BETA BIONICS INC (BBNX) is 12.53% of its float. Check the ownership tab for more information on the BBNX short interest.


BBNX Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to BBNX.


Chartmill TA Rating
Chartmill Setup Rating

BBNX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BBNX. BBNX has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BBNX Financial Highlights

Over the last trailing twelve months BBNX reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -24.17% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -36.59%
ROE -72.04%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%3.93%
Sales Q2Q%144.79%
EPS 1Y (TTM)-24.17%
Revenue 1Y (TTM)442.93%

BBNX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to BBNX. The Buy consensus is the average rating of analysts ratings from 15 analysts.

For the next year, analysts expect an EPS growth of -4.72% and a revenue growth 30.6% for BBNX


Ownership
Inst Owners93.3%
Ins Owners6.51%
Short Float %12.53%
Short Ratio9.75
Analysts
Analysts84
Price Target24.03 (46.35%)
EPS Next Y-4.72%
Revenue Next Year30.6%